Adaptive Biotechnologies is a biotechnology company specializing immune-driven medicine that aims to improve people’s lives by learning from the wisdom of their adaptive immune systems.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
01/04/2018 | Series F-1 | $45MM | $xx.xx | $1.35B | Microsoft | |
Price per Share
$xx.xx
Shares Outstanding
4,217,985
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Microsoft
|
||||||
05/06/2015 | Series F | $195.1MM | $xx.xx | $1.08B | Alexandria Real Estate Equities, Bd Biosciences, Casdin Capital, Celgene, Foresite Capital Management, Illumina, Laboratory Corporation Of America, Matrix Capital Management, Rock Springs Capital, Senator Investment Group, Tiger Global Management, Viking Global Investors | |
Price per Share
$xx.xx
Shares Outstanding
21,761,676
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Real Estate Equities, Bd Biosciences, Casdin Capital, Celgene, Foresite Capital Management, Illumina, Laboratory Corporation Of America, Matrix Capital Management, Rock Springs Capital, Senator Investment Group, Tiger Global Management, Viking Global Investors
|
||||||
01/22/2015 | Series E1 | $105.12MM | $xx.xx | $652.13MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
17,407,441
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
01/21/2015 | Series E | $93.75MM | $xx.xx | $321.37MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
15,524,350
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
07/29/2014 | Series D | $107MM | $xx.xx | $261.89MM | Viking Global Investors | |
Price per Share
$xx.xx
Shares Outstanding
19,269,117
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Viking Global Investors
|
||||||
07/09/2013 | Series C | $5.02MM | $xx.xx | $76.08MM | Ares Capital, Viking Global Investors | |
Price per Share
$xx.xx
Shares Outstanding
1,905,206
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ares Capital, Viking Global Investors
|
||||||
06/02/2011 | Series B | $5.82MM | $xx.xx | $49.04MM | Angel Investors | |
Price per Share
$xx.xx
Shares Outstanding
3,399,033
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Angel Investors
|
||||||
03/24/2010 | Series A | $4.55MM | $xx.xx | $27.52MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
4,550,000
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|